Skip to main content
SpringerLink
Log in

Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity

  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Replacement therapy with exogenous recombinant factor VIII (rFVIII) to control bleeding episodes results in the development of inhibitory antibodies in 15% to 30% of hemophilia A patients. The inhibitory antibodies are mainly directed against specific and universal immunodominant epitopes located in the C2 domain. Previously we have shown that complexation of O-phospho-L-serine (phosphatidylserine head group) with the phospholipid binding region of the C2 domain can lead to an overall reduction in the immunogenicity of rFVIII. Here, we have investigated the hypothesis that dicaproyl phosphatidylserine, a short-chain water-soluble phospholipid, can reduce the immunogenicity of rFVIII. Circular dichroism and fluorescence spectroscopy studies suggest that dicaproyl phosphatidyl-serine interacts with rFVIII, causing subtle changes in the tertiary and secondary structure of the protein. Sandwich enzyme-linked immunosorbent assay studies indicate that dicaproyl phosphatidylserine probably interacts with the phospholipid binding region of the C2 domain. The immunogenicity of FVIII-dicaproyl phosphatidylserine complexes prepared at concentrations above and below the critical micellar concentrations of the lipid were evaluated in hemophilia A mice. Our results suggest that micellar dicaproyl phosphatidylserine may be useful to reduce the immunogenicity of rFVIII preparations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Foster PA, Zimmerman TS. Factor VIII structure and function.Blood Rev. 1989;3:180–191.

    Article  CAS  PubMed  Google Scholar 

  2. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function.Blood. 1998;92:3983–3996.

    CAS  PubMed  Google Scholar 

  3. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor.Nature. 1984;312:342–347.

    Article  CAS  PubMed  Google Scholar 

  4. Kaufiman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells.J Biol Chem. 1988;263:6352–6362.

    Google Scholar 

  5. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII.Nature. 1984;312:337–342.

    Article  CAS  PubMed  Google Scholar 

  6. Fay PJ. Reconstitution of human factor VIII from isolated subunits.Arch Biochem Biophys. 1988;262:525–531.

    Article  CAS  PubMed  Google Scholar 

  7. Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII.J Biol Chem. 1991;266:21948–21955.

    CAS  PubMed  Google Scholar 

  8. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.J Clin Invest. 1977;60:390–404.

    Article  CAS  PubMed  Google Scholar 

  9. Kaufiman RJ, Dorner AJ, Fass DN. von Willebrand factor elevates plasma a factor VIII without induction of factor VIII messenger RNA in the liver.Blood. 1999;93:193–197.

    Google Scholar 

  10. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B.Lancet. 2003;361:1801–1809.

    Article  CAS  PubMed  Google Scholar 

  11. Manco-Johnson M. Hemophilia management: optimizing treatment based on patient needs.Curr Opin Pediatr. 2005;17:3–6.

    Article  PubMed  Google Scholar 

  12. Ananyeva NM, Lacroix-Desmazes S, Hauser CA, et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives.Blood Coagul Fibrinolysis. 2004;15:109–124.

    Article  CAS  PubMed  Google Scholar 

  13. Oldenburg J, Schroder J, Hermann Brackmann H, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibition development.Semin Hematol. 2004;41:82–88.

    Article  CAS  PubMed  Google Scholar 

  14. Saint-Remy JM, Lacroix-Desmazes S, Oldenburg J. Inhibitors in haemophilia: pathophysiology.Haemophilia. 2004;10:146–151.

    Article  PubMed  Google Scholar 

  15. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders.Blood. 2004;104:3858–3864.

    Article  CAS  PubMed  Google Scholar 

  16. Ingerslev J. Hemophilia. Strategies for the treatment of inhibitor patients.Haematologica. 2000;85:15–20.

    CAS  PubMed  Google Scholar 

  17. Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia.Drugs. 2000;60:547–554.

    Article  CAS  PubMed  Google Scholar 

  18. Gensana M, Altisent C, Aznar JA, et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.Haemophilia. 2001;7:369–374.

    Article  CAS  PubMed  Google Scholar 

  19. Lollar P, Healey JF, Barrow RT, Parker ET. Factor VIII inhibitors.Adv Exp Med Biol. 2001;489:65–73.

    CAS  PubMed  Google Scholar 

  20. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII.J Thromb Haemost. 2004;2:1385–1394.

    Article  CAS  PubMed  Google Scholar 

  21. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII.J Thromb Haemost. 2003;1: 1777–1784.

    Article  CAS  PubMed  Google Scholar 

  22. Pratt KP, Qian J, Ellaban E, et al. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site.Thromb Haemost. 2004;92:522–528.

    CAS  PubMed  Google Scholar 

  23. Raju R, Navaneetham D, Okita D, Diethelm-Okita B, McCormick D, Conti-Fine BM. Epitopes for human CD4+ cells on diphtheria toxin: structural features of sequence segments forming epitopes recognized by most subjects.Eur J Immunol. 1995;25:3207–3214.

    Article  CAS  PubMed  Google Scholar 

  24. Purohit VS, Jr, Ramani K, Jr, Sarkar R, Jr, Kazazian HH, Jr, Balasubramanian SV. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.J Biol Chem. 2005;280:17593–17600.

    Article  CAS  PubMed  Google Scholar 

  25. Balasubramanian V, Ramanathan M. Glycosaminoglycans alter the conformation of interferon-gamma.Cytokine. 2000;12:466–471.

    Article  CAS  PubMed  Google Scholar 

  26. Hauser H. Short-chain phospholipids as detergents.Biochim Biophys Acta. 2000;1508:164–181.

    Article  CAS  PubMed  Google Scholar 

  27. Derrick TS, Kashi RS, Durrani M, Jhingan A, Middaugh CR. Effect of metal cations on the conformation and inactivation of recombinant human factor VIII.J Pharm Sci. 2004;93:2549–2557.

    Article  CAS  PubMed  Google Scholar 

  28. Ramani K, Purohit V, Middaugh CR, Balasubramanian SV. Aggregation kinetics of recombinant human FVIII (rFVIII).J Pharm Sci. 2005;94:2023–2029.

    Article  CAS  PubMed  Google Scholar 

  29. Bi L, Jr, Lawler AM, Jr, Antonarakis SE, Jr, High KA, Jr, Gearhart JD, Jr, Kazazian HH, Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.Nat Genet. 1995;10:119–121.

    Article  CAS  PubMed  Google Scholar 

  30. Qian J, Jr, Borovok M, Jr, Bi L, Jr, Kazazian HH, Jr, Hoyer LW. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.Thromb Haemost. 1999;81:240–244.

    CAS  PubMed  Google Scholar 

  31. Chattopadhyay A, London E. Fluorimetric determination of critical micelle concentration avoiding interference from detergent charge.Anal Biochem. 1984;139:408–412.

    Article  CAS  PubMed  Google Scholar 

  32. Zarif L. Drug delivery by lipid cochleates.Methods Enzymol. 2005;391:314–329.

    Article  CAS  PubMed  Google Scholar 

  33. Ramani K, Balasubramanian SV. Fluorescence properties of Laurdan in cochleate phases.Biochim Biophys Acta. 2003;1618: 67–78.

    Article  CAS  PubMed  Google Scholar 

  34. Zhai X, Srivastava A, Drummond DC, Daleke D, Lentz BR. Phosphatidylserine binding alters the conformation and specifically enhances the cofactor activity of bovine factor Va.Biochemistry. 2002;41:5675–5684.

    Article  CAS  PubMed  Google Scholar 

  35. Ramani K, Purohit VS, Miclea RD, Middaugh CR, Balasubramanian SV. Lipid binding region (2303–2332) is involved in aggregation of recombinanty human FVIII (rFVIII).J Pharm Sci. 2005;94:1288–1299.

    Article  CAS  PubMed  Google Scholar 

  36. Tsai PK, Volkin DB, Dabora JM, et al. Formulation design of acidic fibroblast growth factor.Pharm Res. 1993;10:649–659.

    Article  CAS  PubMed  Google Scholar 

  37. Reipert BM, Ahmad RU, Turecek PL, Schwarz HP. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A.Thromb Haemost. 2000;84:826–832.

    CAS  PubMed  Google Scholar 

  38. Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A.Blood. 2000;95:1324–1329.

    CAS  PubMed  Google Scholar 

  39. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.Thromb Haemost. 2002;88:221–229.

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Vivek S. Purohit

    Present address: Eurand, Inc, 845 Center Drive, Vandalia, OH, 45377

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, University at Buffalo State University of New York, 527 Hochstetter Hall, 14260-1200, Amherst, NY

    Vivek S. Purohit & Sathyamangalam V. Balasubramanian

Authors
  1. Vivek S. Purohit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sathyamangalam V. Balasubramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Published: May 26, 2006

Rights and permissions

Reprints and permissions

About this article

Cite this article

Purohit, V.S., Balasubramanian, S.V. Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity. AAPS J 8, 41 (2006). https://doi.org/10.1007/BF02854907

Download citation

  • Received:

  • Accepted:

  • DOI: https://doi.org/10.1007/BF02854907

Keywords

Search

Navigation